Skip to main content
mRNA pipeline

Research

Browse:

Our mRNA pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions.

Scientist looking at lab gear
Close up of pipet putting water droplet on petri dish
All Categories
Program Indication
ID #
Preclinical Development
Phase 1
Phase 2
Phase 3
Commercial
Moderna rights

Infectious Disease Vaccines

Adults

COVID-19 vaccine
Spikevax®
Commercial
Moderna rights:Worldwide
COVID-19 vaccineNext generation (2-5 ºC)
mRNA-1283
Phase 3
Moderna rights:Worldwide
Flu vaccine
mRNA-1010
Phase 3
Moderna rights:Worldwide
Flu vaccine
mRNA-1020
Phase 2
Moderna rights:Worldwide
Flu vaccine
mRNA-1030
Phase 2
Moderna rights:Worldwide
Flu vaccine
mRNA-1011
Phase 2
Moderna rights:Worldwide
Flu vaccine
mRNA-1012
Phase 2
Moderna rights:Worldwide
RSV vaccineolder adults
mRESVIA®
Commercial
Moderna rights:Worldwide
RSV vaccine18-59 high risk
mRNA-1345
Phase 3
Moderna rights:Worldwide
Flu + COVID vaccine
mRNA-1083
Phase 3
Moderna rights:Worldwide
Flu + COVID + RSV vaccine
mRNA-1230
Phase 1
Moderna rights:Worldwide
Flu + RSV vaccine
mRNA-1045
Phase 1
Moderna rights:Worldwide
Pandemic Flu vaccine
mRNA-1018
Phase 2
Moderna rights:Worldwide
RSV + hMPV vaccine
mRNA-1365
Phase 1
Moderna rights:Worldwide

Adolescents and Pediatrics

COVID-19 vaccine (adolescents)TeenCOVE
Spikevax®
Commercial
Moderna rights:Worldwide
COVID-19 vaccine (pediatrics)KidCOVE
mRNA-1273.815
Commercial
Moderna rights:Worldwide
Pediatric RSV vaccine
mRNA-1345
Phase 2
Moderna rights:Worldwide

Latent & Public Health Vaccines

Latent Vaccines

CMV vaccine
mRNA-1647
Phase 3
Moderna rights:Worldwide
EBV vaccine (to prevent infectious mononucleosis)
mRNA-1189
Phase 1
Moderna rights:Worldwide
EBV vaccine (to address long term EBV sequelae)
mRNA-1195
Phase 1
Moderna rights:Worldwide
HSV vaccine
mRNA-1608
Phase 2
Moderna rights:Worldwide
VZV vaccine
mRNA-1468
Phase 2
Moderna rights:Worldwide
HIV vaccine
mRNA-1644
Phase 1
Moderna rights:Worldwide (IAVI/others funded)
HIV vaccine
mRNA-1574
Phase 1
Moderna rights:Worldwide (IAVI/BMGF/NIAID and others funded)

Enteric Vaccines

Norovirus vaccine
mRNA-1403
Phase 3
Moderna rights:Worldwide
Norovirus vaccine
mRNA-1405
Phase 2
Moderna rights:Worldwide

Bacterial Vaccines

Lyme disease vaccine
mRNA-1975
Phase 2
Moderna rights:Worldwide
Lyme disease vaccine
mRNA-1982
Phase 2
Moderna rights:Worldwide

Public Health Vaccines

Zika vaccine
mRNA-1893
Phase 2
Moderna rights:Worldwide (BARDA funded)
Nipah vaccine
mRNA-1215
Phase 1
Moderna rights:Worldwide (NIH funded)
Mpox vaccine
mRNA-1769
Phase 1
Moderna rights:Worldwide

Therapeutics

CANCER VACCINES & THERAPEUTICS

Individualized neoantigen therapy (INT) – adjuvant melanoma
mRNA-4157
Phase 3
Moderna rights:50-50 global profit sharing with Merck
Individualized neoantigen therapy (INT) – adjuvant NSCLC
mRNA-4157
Phase 3
Moderna rights:50-50 global profit sharing with Merck
Individualized neoantigen therapy (INT) – adjuvant NSCLC post neoadjuvant treatment
mRNA-4157
Phase 3
Moderna rights:50-50 global profit sharing with Merck
Individualized neoantigen therapy (INT) – cutaneous squamous cell carcinoma (cSCC)
mRNA-4157
Phase 2
Moderna rights:50-50 global profit sharing with Merck
Individualized neoantigen therapy (INT) – renal cell carcinoma (RCC)
mRNA-4157
Phase 2
Moderna rights:50-50 global profit sharing with Merck
Individualized neoantigen therapy (INT) – bladder cancer
mRNA-4157
Phase 2
Moderna rights:50-50 global profit sharing with Merck
Checkpoint vaccine
mRNA-4359
Phase 2
Moderna rights:Worldwide

Rare disease intercellular therapeutics

Propionic acidemia (PA)
mRNA-3927
Phase 2
Moderna rights:Worldwide
Methylmalonic acidemia (MMA)
mRNA-3705
Phase 2
Moderna rights:Worldwide
Glycogen Storage Disease Type 1a (GSD1a)
mRNA-3745
Phase 1
Moderna rights:Worldwide
Ornithine transcarbamylase deficiency (OTC)
mRNA-3139
Preclinical Development
Moderna rights:Worldwide
Phenylketonuria (PKU)
mRNA-3210
Preclinical Development
Moderna rights:Worldwide
Crigler-Najjar Syndrome Type 1 (CN-1)
mRNA-3351
Preclinical Development
Moderna rights:Provided to Institute for Life Changing Medicines (ILCM) free of charge

Inhaled Pulmonary Therapeutics

Cystic fibrosis (CF)
mRNA-3692 / VX-522
Phase 1
Moderna rights:Vertex to pay milestones and royalties